Missoula, MT, April 15, 2025 – Inimmune, a clinical-stage biotechnology company specializing in next generation vaccine adjuvants, immunotherapies, and delivery systems, is excited to announce its participation in the 2025 World Vaccine Congress, taking place April 21–24 in Washington, DC. The company will share exciting progress from its clinical-stage immunotherapy and vaccine programs, and take part in shaping the conversation on the future of vaccinology and immunology.
Inimmune’s leadership team will be prominently featured throughout the event:
- Dr. David Burkhart, Chief Executive Officer, will serve as both Chair and Speaker during the Vaccine Technologies Workshop on Monday, April 21.
- Dr. Jay Evans, Chief Scientific and Strategy Officer, will also be a Chair, Speaker, and Featured Panelist in the Alternative Vaccine Targets Workshop, also on Monday, April 21.
- Dr. Shannon Miller, Vice President of Operations, will Chair a Session on Immune Profiling and moderate a panel discussion on AI and predictive technologies for vaccine safety and immunogenicity on Thursday, April 24.
As the world’s largest gathering of vaccine innovators, the World Vaccine Congress provides an unparalleled platform for collaboration and discovery. Inimmune is proud to be at the forefront of this dynamic global dialogue and looks forward to highlighting the company’s impressive momentum across both clinical and preclinical programs.
Learn more about the conference here: World Vaccine Congress Washington
